HSP90 inhibitor modulates HMGA1 and HMGB2 expression along with cell viability via NF-KB signaling pathways in melanoma in-vitro

Shomali, Navid; Marofi, Faroogh; Tarzi, Saeed; Tamjdidfar, Rozita; Akbari, Morteza; Parvari, Soraya; Sadeghvand, Shahram; Deljavan, Mina; Moridi, Osameh; Javadi, Meisam; Shotorbani, Siamak Sandoghchian

doi:10.1016/j.genrep.2021.101205

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is limited evidence that BRCA1 mutation carriers have a modestly elevated risk of serous endometrial cancer. However, according to the latest research, the clinical implications are still up in the air [15,28,29]. Breast and ovarian cancers are linked with a cumulative risk of nearly 72 percent and 44 percent, respectively, for BRCA1 mutation carriers and 69 percent and 17 percent for BRCA2 mutation carriers until 80 years [30].…”

Section: Ovarian Cancer Progression and Genetic Alterationsmentioning

confidence: 99%

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

et al. 2022

Self Cite

View full text Add to dashboard Cite

Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics.

show abstract

Section: Ovarian Cancer Progression and Genetic Alterationsmentioning

confidence: 99%

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Breast cancer is divided into molecular subsets with distinctive biology and clinical characteristics 1,2 . Every year, almost 2 million new breast cancer cases are identified worldwide, and over half a million individuals die from the disease due to recurrence or metastasis 3–6 . Early detection and significant advances in standard conventional modalities (e.g., chemotherapy, radiotherapy, surgery, and hormone therapy) have improved cure rates and quality of life in women with localized breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 Every year, almost 2 million new breast cancer cases are identified worldwide, and over half a million individuals die from the disease due to recurrence or metastasis. 3 , 4 , 5 , 6 Early detection and significant advances in standard conventional modalities (e.g., chemotherapy, radiotherapy, surgery, and hormone therapy) have improved cure rates and quality of life in women with localized breast cancer. At the same time, some subsets with distant metastases remain the primary concern for treatment.…”

Section: Introductionmentioning

confidence: 99%

Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances

Nikoo

Rudiansyah

Bokov

et al. 2022

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Despite substantial developments in conventional treatments such as surgery, chemotherapy, radiotherapy, endocrine therapy, and molecular‐targeted therapy, breast cancer remains the leading cause of cancer mortality in women. Currently, chimeric antigen receptor (CAR)–redirected immune cell therapy has emerged as an innovative immunotherapeutic approach to ameliorate survival rates of breast cancer patients by eliciting cytotoxic activity against cognate tumour‐associated antigens expressing tumour cells. As a crucial component of adaptive immunity, T cells and NK cells, as the central innate immune cells, are two types of pivotal candidates for CAR engineering in treating solid malignancies. However, the biological distinctions between NK cells‐ and T cells lead to differences in cancer immunotherapy outcomes. Likewise, optimal breast cancer removal via CAR‐redirected immune cells requires detecting safe target antigens, improving CAR structure for ideal immune cell functions, promoting CAR‐redirected immune cells filtration to the tumour microenvironment (TME), and increasing the ability of these engineered cells to persist and retain within the immunosuppressive TME. This review provides a concise overview of breast cancer pathogenesis and its hostile TME. We focus on the CAR‐T and CAR‐NK cells and discuss their significant differences. Finally, we deliver a summary based on recent advancements in the therapeutic capability of CAR‐T and CAR‐NK cells in treating breast cancer.

show abstract

“…Shomali et al's study suggested that HSP90 may act as a potential therapeutic target in melanoma. However, more studies are needed to determine the exact role of HSP90 and its association with HMG genes [ 15 ]. At present, there are mainly immunotherapy, braf/mek inhibitors, and other methods for the treatment of melanoma.…”

Section: Introductionmentioning

confidence: 99%

Global Trends in Research of NF-κB in Melanoma from 2000 to 2021: A Study of Bibliometric Analysis

Wang

Liao

Jiang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

In the pathogenesis of melanoma, NF-κB is a key signaling pathway. Appling bibliometric analysis, we identify the frontiers and hotspots about NF-κB in melanoma, as well as distinguishing features of scientific research and output all over the world during the past 22 years. 2226 publications published from 2000 to 2021 and related information were retrieved based on Science Citation Index Expanded (SCI-expanded) of Web of Science Core Collection (WoSCC). VOSviewer and Citespace were used to analyze bibliometric indicators and visualize the hotspots and research trend of studies on NF-κB in melanoma. The results indicated that despite fluctuations, the number of publications (Np) related to the research of NF-κB in melanoma per year increased over the past 22 years. The USA had the most publications. H-index and the number of citations (Nc) of the USA were also in the first place. PloS One was the most productive journal, and League of European Research Universities (LERU) was the most productive affiliation. Recently, the keywords “NF-kappa-b,” “melanoma,” “apoptosis,” “expression,” “activation,” “cancer,” and “metastasis” appeared most frequently. Our study suggested that articles associated with NF-κB in melanoma tend to increase. In this field, the USA was an influential country and a big producer. Most publications focused on clinical and basic research in the past 22 years, and keywords “tumor necrosis factor” and “trail induced apoptosis” had the highest burst strength.

show abstract

HSP90 inhibitor modulates HMGA1 and HMGB2 expression along with cell viability via NF-KB signaling pathways in melanoma in-vitro

Cited by 6 publications

References 31 publications

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances

Global Trends in Research of NF-κB in Melanoma from 2000 to 2021: A Study of Bibliometric Analysis

Contact Info

Product

Resources

About